Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors

被引:27
|
作者
Breuker, Cyril [1 ,2 ]
Clement, Florian [1 ]
Mura, Thibault [3 ]
Macioce, Valerie [3 ]
Castet-Nicolas, Audrey [1 ,5 ]
Audurier, Yohan [1 ]
Boegner, Catherine [4 ]
Morcrette, Emilie [4 ]
Jalabert, Anne [1 ]
Villiet, Maxime [1 ]
Avignon, Antoine [2 ,4 ]
Sultan, Ariane [2 ,4 ]
机构
[1] Univ Hosp, Clin Pharm Dept, 191 Ave Doyen Gaston Giraud, F-34295 Montpellier, France
[2] Univ Montpellier, CNRS, INSERM, PhyMedExp, Montpellier, France
[3] Univ Hosp, Clin Res & Epidemiol Unit, Montpellier, France
[4] Univ Hosp, Endocrinol Diabetol Nutr Dept, Montpellier, France
[5] Univ Montpellier, IRCM INSERM U1194, Montpellier, France
关键词
Type; 2; diabetes; Low-density lipoprotein cholesterol; Cardiovascular risk; Lipid-lowering therapy; ESC/EAS GUIDELINES; LOWERING THERAPY; MANAGEMENT; DISEASE; INTERVENTIONS; DYSLIPIDEMIA; ASSOCIATION; ATTAINMENT; ADHERENCE; PEOPLE;
D O I
10.1016/j.ijcard.2018.04.068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiovascular diseases are the first cause of mortality in patients with diabetes, and LDL-cholesterol is a well-established cardiovascular risk factor. This study aimed to assess rate of LDL-cholesterol target attainment among patients with diabetes at very-high cardiovascular risk treated with statins, and to identify predictive factors of non-attainment of target in this population. Methods: Patients were recruited in the Nutrition-Diabetes unit of Montpellier University Hospital, France, from 2014 to 2017. We included all consecutive patients with type 1 or type 2 diabetes receiving statin treatment and at very-high cardiovascular risk according to 2016 ESC guidelines, therefore having a LDL-cholesterol target of <1.8 mmol/L. LDL-cholesterol levels were measured upon admission. Variables independently associated with non-attainment of LDL-Cholesterol target were assessed using multivariable logistic regression. Results: 654 patients were included. Mean age was 63.8 years (SD 11.0), 41.9% were women and 42.3% had a history of cardiovascular disease. 59% of patients did not achieve LDL-cholesterol target, with a median value (inter-quartile range) of 2.4 mmol/L (2.1-2.9) versus 1.4 mmol/L (1.1-1.6) in patients at target. Risk of non-attainment of LDL-cholesterol target value was increased in women (odds ratio [95% confidence interval]: 2.27 [1.62-3.17]) and decreased in patients with history of coronary artery disease (0.64 [0.45-0.89]) or history of stroke or transient ischemic attack (0.59 [0.33-1.07]). Conclusions: Management of dyslipidemia is suboptimal, even in very-high risk patients with diabetes under statins. Lipid-lowering treatment should be intensified, in particular in very high risk patients with diabetes who are women or in primary cardiovascular prevention. (c) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:195 / 199
页数:5
相关论文
共 50 条
  • [31] Reaching LDL-C Targets in Patients with Moderate, High, and Very High Risk for Cardiovascular Disease After Bariatric Surgery According to Different Guidelines
    Guillermo Ponce de León-Ballesteros
    Hugo A. Sánchez-Aguilar
    Carlos A. Aguilar-Salinas
    Miguel F. Herrera
    Obesity Surgery, 2021, 31 : 2087 - 2096
  • [32] Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry
    De Luca, Leonardo
    Arca, Marcello
    Temporelli, Pier Luigi
    Meessen, Jennifer
    Riccio, Carmine
    Bonomo, Paolo
    Colavita, Angela Rita
    Gabrielli, Domenico
    Gulizia, Michele Massimo
    Colivicchi, Furio
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 316 : 229 - 235
  • [33] New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
    Burger, Achim Leo
    Pogran, Edita
    Muthspiel, Marie
    Kaufmann, Christoph Clemens
    Jaeger, Bernhard
    Huber, Kurt
    BIOMEDICINES, 2022, 10 (05)
  • [34] Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels
    Querton, Laurent
    Buysschaert, Martin
    Hermans, Michel P.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (05) : 434 - 442
  • [35] Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study
    Ray, Kausik K.
    Haq, Inaam
    Bilitou, Aikaterini
    Manu, Marius C.
    Burden, Annie
    Aguiar, Carlos
    Arca, Marcello
    Connolly, Derek L.
    Eriksson, Mats
    Ferrieres, Jean
    Laufs, Ulrich
    Mostaza, Jose M.
    Nanchen, David
    Rietzschel, Ernst
    Strandberg, Timo
    Toplak, Hermann
    Visseren, Frank L. J.
    Catapano, Alberico L.
    LANCET REGIONAL HEALTH-EUROPE, 2023, 29
  • [36] Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry
    Shoji, Satoshi
    Shah, Nishant P.
    Shrader, Peter
    Thomas, Laine E.
    Arnold, Jonathan D.
    Dhalwani, Nafeesa N.
    Thomas, Neena A.
    Kalich, Bethany
    Priest, Elisa L.
    Syed, Mahanaz
    Wojcik, Cezary
    Peterson, Eric D.
    Navar, Ann Marie
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2025, 21
  • [37] Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk: The influence of baseline medication on LDL-cholesterol, blood pressure and calculated risk reduction when switching to a cardiovascular polypill
    Lafeber, Melvin
    Spiering, Wilko
    Visseren, Frank L. J.
    Grobbee, Diederick E.
    Bots, Michiel L.
    Stanton, Alice
    Patel, Anushka
    Prabhakaran, Dorairaj
    Webster, Ruth
    Thom, Simon
    Rodgers, Anthony
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (09) : 951 - 961
  • [38] Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease
    Vaverkova, Helena
    Farnier, Michel
    Averna, Maurizio
    Missault, Luc
    Viigimaa, Margus
    Dong, Qian
    Shah, Arvind
    Johnson-Levonas, Amy O.
    Brudi, Philippe
    CLINICAL BIOCHEMISTRY, 2011, 44 (8-9) : 627 - 634
  • [39] The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study
    Danese, Mark D.
    Sidelnikov, Eduard
    Kutikova, Lucie
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1441 - 1447
  • [40] Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China
    Wang, Xing
    He, Yan
    Wang, Tao
    Li, Chunming
    Ma, Zihui
    Zhang, Heng
    Ma, Handong
    Zhao, Hongxin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (04) : 307 - 315